Dr Mohamed Salem talks to ecancer about a talk he presented at ESMO GI 2022 on the impact of BRAF-V600E mutation on immunologic characteristics of the tumour microenvironment and associated genomic alterations in microsatellite instability-high (MSI-H) or mismatch-repair-deficient colorectal cancer.
He begins by explaining the rationale behind the study before detailing the design and patient criteria.
Dr Salem believes that the results show that, among those tumours with MSI-H status, there is no significant difference in the tumour microenvironment with BRAF-V600E mutation or wild-type status, suggesting that both should be equally responsive.